Literature DB >> 8953669

Short-term IgM and IgG antibody responses to hepatitis E virus infection.

A Koshy1, S Grover, K C Hyams, M A Shabrawy, A Pacsa, B al-Nakib, S A Zaidi, A A al-Anezi, S al-Mufti, J Burans, M Carl, A L Richards.   

Abstract

53 adult patients with acute hepatitis caused by hepatitis E virus were identified by the presence of IgM antibody to hepatitis E virus, and followed for 12 months to evaluate the kinetics of anti-HEV antibodies. All but 1 female Kuwaiti patient were expatriate workers from the Indian subcontinent, temporarily working in Kuwait. Follow-up samples obtained at 1, 3, 6 and 12 months were evaluated for IgM and IgG antibodies to hepatitis E virus. IgM-class antibodies to hepatitis E virus were detectable in 12/27 (44%) patients at 1 months, in 0/26 at 3 months, in 0/8 at 6 months and 0/6 at 12 months. IgG antibodies to hepatitis E virus were detectable in 46/47 (98%) at onset, 26/27 (96%) at 1 month, in 26/29 (90%) at 3 months, 16/16 (100%) at 6 months and 8/8 (100%) at 12 months of follow-up. This study suggests that IgM antibodies to hepatitis E virus decline rapidly after an acute infection but IgG antibodies to hepatitis E virus persists for at least 1 year in many patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8953669     DOI: 10.3109/00365549609037935

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  10 in total

1.  Hepatitis E infection.

Authors:  Vincent C Kuo
Journal:  Proc (Bayl Univ Med Cent)       Date:  2012-04

Review 2.  Host immune status and response to hepatitis E virus infection.

Authors:  Lisa J Krain; Kenrad E Nelson; Alain B Labrique
Journal:  Clin Microbiol Rev       Date:  2014-01       Impact factor: 26.132

3.  Detection of hepatitis E virus-specific immunoglobulin a in patients infected with hepatitis E virus genotype 1 or 3.

Authors:  M Herremans; E Duizer; E Jusic; M P G Koopmans
Journal:  Clin Vaccine Immunol       Date:  2007-01-31

4.  Diagnostic value of immunoglobulin G (IgG) and IgM anti-hepatitis E virus (HEV) tests based on HEV RNA in an area where hepatitis E is not endemic.

Authors:  C C Lin; J C Wu; T T Chang; W Y Chang; M L Yu; A W Tam; S C Wang; Y H Huang; F Y Chang; S D Lee
Journal:  J Clin Microbiol       Date:  2000-11       Impact factor: 5.948

5.  Seroprevalence of hepatitis E virus (HEV) antibody and the possible association with chronic liver disease: a case-control study in Albania.

Authors:  L A Kondili; P Chionne; A Porcaro; E Madonna; S Taffon; B Resuli; G Taliani; M Rapicetta
Journal:  Epidemiol Infect       Date:  2006-02       Impact factor: 2.451

6.  Synthetic rabbit-human antibody conjugate as a control in immunoassays for immunoglobulin M specific to hepatitis E virus.

Authors:  Kuo Zhang; Lunan Wang; Min Liu; Rui Zhang; Jinming Li
Journal:  Virol J       Date:  2010-05-20       Impact factor: 4.099

Review 7.  Hepatitis E vaccines: progress and prospects.

Authors:  Harald Claus Worm; Gerhard Wirnsberger
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  Clinical significance of anti-HEV IgA in diagnosis of acute genotype 4 hepatitis E virus infection negative for anti-HEV IgM.

Authors:  Shujun Zhang; Deying Tian; Zhengang Zhang; Junhui Xiong; Quan Yuan; Shengxiang Ge; Jun Zhang; Ningshao Xia
Journal:  Dig Dis Sci       Date:  2009-01-01       Impact factor: 3.199

9.  Epidemiology and associated risk factors of hepatitis e virus infection in plateau state, Nigeria.

Authors:  Surajudeen A Junaid; Samuel E Agina; Khadijah A Abubakar
Journal:  Virology (Auckl)       Date:  2014-05-27

10.  High Hepatitis E Seroprevalence Among Displaced Persons in South Sudan.

Authors:  Andrew S Azman; Malika Bouhenia; Anita S Iyer; John Rumunu; Richard Lino Laku; Joseph F Wamala; Isabel Rodriguez-Barraquer; Justin Lessler; Etienne Gignoux; Francisco J Luquero; Daniel T Leung; Emily S Gurley; Iza Ciglenecki
Journal:  Am J Trop Med Hyg       Date:  2017-06       Impact factor: 2.345

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.